What happens when we sneeze, and why does it feel good?
Here's what happens in your body when you sneeze
Here's what happens in your body when you sneeze
Here's what happens in your body when you sneeze
The sights of summer, like flowers and grass, can lead to the sound of sneezing. For some, it's constant, for others, it's sporadic, but we all know how it feels.
"When we get exposed to dust, strong smells, perfume, cigarette smoke, you are going to sneeze," said Dr. Pramod Kelkar, an allergist with Allina Health.
Sometimes even the sun can make some people sneeze.
"The brightness, the light can also trigger this lining of the nose," Kelkar said.
Kelkar says sneezing is a neurological reflex.
"The nerve impulses, they send a signal to the brain stem, where the sneezing center is located. Once the brain stem receives that signal, it sends a signal back to the motor neurons, that means muscles of the chest, the abdomen and throat area. They constrict, they increase the pressure, they constrict. Mouth opens, the nose opens and the air is pushed out at about 100 mph to get rid of that dust, to get rid of whatever foreign body is going into the respiratory track."
That's why it's key to muffle and cover a sneeze. The National Institute of Health reports, "A sneeze can create 40,000 virus-containing droplets that reach a radius of 7-8 meters and suspend in the air for up to 10 minutes."
So why does our body have such a dramatic response to simply protect?
"Because if the air is not coming out at high speed, you will not be able to get rid of that dust particle. So it is a protective mechanism," Kelkar said.
It's a process that sounds painful, but, oddly, it's the opposite. Some people say it feels "good" after you sneeze.
"So the pressure is building in your chest, in the abdomen, in the throat area, that pressure is relieved. So you feel like that," Kelkar said.
Research also shows some endorphins are released, creating a natural runner's high.
Even though they are tough to suppress, sneezes are quick to endure.
Kelkar says some people are triggered to sneeze when they walk in and out of warm and cold environments. He says the best way to get ahead of sneezes is to do a daily saline nose spray or rinse.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Cytovale's Rapid Diagnostic Slashes Sepsis Mortality by 39%, Peer-Reviewed Study Confirms
Cytovale's IntelliSep® sepsis test highlights a new model for ED triage that's already delivering systemwide clinical and economic value Results of real-world study with 12,000+ patients published in the journal Healthcare SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale's IntelliSep®, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay and enabled more efficient resource allocation in the emergency department (ED). The study, "Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes," published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La. "This is the kind of data the medical field has been waiting for and the results represent a breakthrough in sepsis care," said Dr. Christopher Thomas, study author who serves as Vice President and Chief Quality Officer at Franciscan Missionaries of Our Lady Health System (FMOLHS) and is a critical care physician at Louisiana State University Health Sciences Center. "With this small operational change, we are able to save more lives, deliver better care faster and optimize use of hospital resources. It's a pivotal step forward in how emergency departments manage sepsis. With IntelliSep, we've discovered a new way to save lives." Key Study Findings 39% relative rate reduction in sepsis mortality, with non-sepsis mortality unchanged, validating the impact of IntelliSep on targeted triage. 0.76 day decrease in average hospital length of stay for sepsis patients, with strong implications for improved throughput and cost reduction. 40% decrease in blood culture usage in low risk patients and an 8% increase in high-risk cases, underscoring the ability of IntelliSep to help providers fine-tune diagnostic precision. Detecting Sepsis in Minutes, Bringing Speed and Confidence to the FrontlineSepsis is one of the most elusive and deadly conditions in modern medicine, responsible for nearly one in three hospital deaths in the United States. EDs often err on the side of caution, treating a wide range of incoming patients as potentially septic because there is a lack of reliable, objective methods for early risk assessment. Treating every patient as potentially septic, while understandable in a high-stakes environment like the ED, often results in unnecessary, non-beneficial interventions for patients who likely do not have sepsis. The strains on limited ED resources was a top concern for OLOLRMC when it implemented IntelliSep as part of a nurse-driven sepsis triage initiative designed to identify and rapidly triage patients at highest risk. IntelliSep is the first and only FDA-cleared diagnostic to aid in early sepsis detection in the ED. Using a routine blood draw, the test delivers results in about eight minutes. This helps clinicians to rule in or rule out sepsis even before clinical signs are fully visible, giving them greater confidence to determine which patients are in most urgent need of care. The combination of a rapid diagnostic and a protocolized workflow has yielded what the study authors describe as a "game-changing model" for health systems nationwide. "This is more than an innovation – it's a paradigm shift in how health systems are managing sepsis," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC. "For decades, sepsis mortality rates have remained stagnant because we've lacked a fast, reliable way to catch sepsis early. This study proves that with speed, objectivity and accuracy at the point of triage, we can change outcomes before antibiotics are given or ICU beds are needed. That's where real transformation begins." Validated in One Hospital, Scaled Across the Health SystemSepsis is not just a clinical challenge, it's a financial one. For hospitals with more than 500 beds, annual sepsis-related costs can exceed $34 million. A bet on a new approach to sepsis care paid off for OLOLRMC. Reflecting its confidence in IntelliSep's clinical and operational impact at scale, the system's leadership has expanded IntelliSep across four additional sites within FMOLHS. "As health systems face mounting pressures to deliver efficient, effective care, adopting this precise, rapid method will be key to saving lives and controlling costs," Dr. Thomas added. "Those who embrace this approach position themselves at the forefront of sepsis care innovation." About Cytovale®Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit and follow Cytovale on LinkedIn and X. View original content to download multimedia: SOURCE Cytovale Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
35 minutes ago
- New York Times
Trump Administration Live Updates: Lawyers Request Release of Salvadoran Man Until Trial
Health Secretary Robert F. Kennedy Jr. on Wednesday named eight doctors and researchers, including four who have spoken out against vaccination in some way, to replace roughly half the members he fired from an expert panel that advises the Centers for Disease Control and Prevention. Mr. Kennedy made the announcement Wednesday on the social media platform X, two days after he fired all 17 members of the Advisory Committee on Immunization Practices. Arriving at the John F. Kennedy Center for the Performing Arts for a performance of 'Les Misérables' that President Trump also attended, the health secretary told reporters that the firings were 'a long time coming.' Mr. Kennedy said on X that his picks included 'highly credentialed scientists, leading public-health experts, and some of America's most accomplished physicians.' In a post on X late Tuesday night, a day after he removed the panel members, Mr. Kennedy promised he would not appoint 'ideological anti-vaxxers.' After the new list was announced, infectious disease and vaccine experts immediately accused the health secretary of breaking his word. When Mr. Kennedy fired the entire committee, known as the A.C.I.P., he cited financial conflicts of interest and said a clean sweep was necessary to restore public trust in vaccination. But a White House official and a person close to Mr. Kennedy said on Tuesday that ideology was also at work. In addition to supposed financial conflicts, Mr. Kennedy was concerned that all of the members had been appointed by former President Joseph R. Biden Jr., and that some had donated to Democrats. The disclosure was shocking to public health leaders, who say that scientific advisers are chosen for their expertise, without consideration of party affiliation. 'The biggest hit here is the irony of him, RFK, talking about regaining the public's trust,' said Dr. Paul Offit of the Children's Hospital of Philadelphia, who has served as a committee member and has frequently tangled with Mr. Kennedy. 'What he just did was, he lost the trust of the medical community,' Dr. Offit added, 'so much so that people are thinking, 'Should we try and create our own A.C.I.P., our own vaccine advisory committee?' Because you can't trust this one.' The eight members Mr. Kennedy named — seven men and one woman — have varied credentials. All are either medical doctors or have doctorates. They include a psychiatrist; a biostatistician; an expert in health care analytics; a biochemist; a pediatrician; an emergency medical doctor; a public health and critical care nurse; and an obstetrician. Richard H. Hughes IV, who teaches vaccine law at George Washington University Law School, called out one of the new committee members — Dr. Cody Meissner — as a 'legitimate vaccinologist.' Dr. Meissner, a professor of pediatrics at Dartmouth, has previously held advisory roles both with the C.D.C. and the Food and Drug Administration. Dr. Offit and other experts praised Dr. Meissner for his depth of knowledge about vaccines. Mr. Hughes said three of the new members are 'legitimate physicians' who have 'no discernible expertise' in immunology or vaccines. But he characterized the remaining four as 'Covid-19 deniers, skeptics and outright anti-vaccine individuals.' By far the most contentious pick, and the one with the highest profile, is Dr. Robert Malone. He played an early role in mRNA research and has claimed to be the inventor of the technology. He became a right-wing star after a 2021 appearance on 'The Joe Rogan Experience' that exposed both him and Mr. Rogan to criticism that they had spread misinformation. Dr. Malone was a vocal critic of the Biden administration's Covid response. 'Malone has a well-documented history of promoting conspiracy theories and unproven treatment like ivermectin and hydroxychloroquine for Covid-19,' said Dr. Jeffrey D. Klausner, an epidemiologist and infectious disease expert at the University of Southern California. Dr. Klausner, who is also a neighbor of Mr. Kennedy's in Los Angeles and has spoken with the health secretary about possible candidates for advisory committees, said he was 'disappointed' in Dr. Malone's appointment, which he said was likely 'a political move to maintain support of some Americans and demonstrate diversity, equity and inclusivity.' Martin Kulldorff, a Swedish biostatistician and former Harvard professor, has been generally supportive of vaccines, and has advised the C.D.C. on vaccine safety. But he opposed Covid vaccine mandates and Covid vaccination for children, and became caught up in pandemic politics in 2020 as a lead author of the Great Barrington Declaration, a document that opposed lockdowns. The declaration, whose lead authors also included Dr. Jay Bhattacharya, the current director of the National Institutes of Health, garnered nearly one million signatures from more than 40 countries. Dr. Meissner, the new A.C.I.P. member, was an early signer. But it drew intense backlash from Dr. Anthony S. Fauci and other public health leaders, who branded it dangerous. Dr. Francis S. Collins, the N.I.H. director at the time, called the authors 'fringe epidemiologists.' Dr. Kulldorff was later fired from his hospital, Mass General Brigham, and from Harvard, in a dispute over the hospital's requirement for staff to be vaccinated against Covid-19. He has said that he has an immune deficiency, which made him wary of the Covid shot, and that he already had natural immunity from a previous infection. While Dr. Malone and Dr. Kulldorff are the best known of the new members, two other picks — Retsef Levi and Vicky Pebsworth, a nurse — are also likely to come under scrutiny from public health leaders. Dr. Levi, an expert in analytics, risk management and health systems at the Massachusetts Institute of Technology, has criticized school closures and Covid lockdowns, and warned against mRNA vaccines. In a 2023 post on X, he wrote, 'The evidence is mounting and indisputable that mRNA vaccines cause serious harm including death, especially among young people.' He has said the evidence for vaccinating against Covid-19 in pregnancy 'is particularly thin.' After Mr. Kennedy's announcement, Dr. Levi said on Wednesday on X that he was 'honored with this opportunity and humbled by the responsibility' to serve on the panel. Dr. Pebsworth, who has a Ph.D. in public health, serves on the board of the National Vaccine Information Center, founded in 1982 to promote awareness of the risks of vaccination. She has served as a consumer representative to an expert panel that advises the F.D.A. on vaccination and has advised the government in other capacities. In its early years, the vaccine information center worked with federal authorities to promote vaccine safety, and to create a system to address vaccine injuries. But today, advocates for vaccination consider it an anti-vaccine group. Dr. Pebsworth's bio on the center's website says she is the parent of a vaccine-injured child. 'Her son — her only child — experienced serious, long-term health problems following receipt of seven live virus and killed bacterial vaccines administered during his 15-month well-baby visit, which sparked her interest in vaccine safety research and policymaking, and chronic illness and disability in children,' the site says. It is unclear how the committee will move forward with an entirely new membership. Its next meeting is set for later this month. Committee members had expected to discuss, among other things, a change in the vaccination schedule for the human papillomavirus vaccine, but it does not appear as though there is an agenda on the committee's website. 'This is a very differently constituted committee than what we've had before,' said Dr. Yvonne Maldonado, a pediatrician and professor at Stanford University who was among the members fired on Monday. She predicted it would be 'very difficult to get through the agenda in a smooth way,' given that the new panel will have only two weeks to prepare. Javier C. Hernández and Apoorva Mandavilli contributed reporting,
Medscape
an hour ago
- Medscape
Family Ties May Shape Hashimoto Thyroiditis Risk
The odds of developing Hashimoto thyroiditis (HT) were significantly elevated in first-, second-, and third-degree relatives of patients with HT, with female relatives having a disproportionately higher likelihood. Of note, the odds of developing HT were elevated among spouses of patients. METHODOLOGY: Relatives of patients with HT are at an increased risk for HT; however, studies have primarily focused on first-degree relatives and often employed very small sample sizes. Researchers conducted a retrospective case-control study using genealogical and medical data from a Utah-based database (1996-2021) to estimate the risk for HT in relatives across various degrees of relatedness. They included 92,405 adult HT probands (73% women; 96% White individuals) and 184,810 matched control individuals, along with 2,960,650 first-, second-, and third-degree relatives of HT probands and 5,730,159 relatives of control individuals. TAKEAWAY: Relatives of patients with HT were at an increased risk for the condition, with the highest odds observed for first-degree relatives (odds ratio [OR], 1.77; 95% CI, 1.74-1.80), followed by second-degree (OR, 1.23; 95% CI, 1.22-1.27) and third-degree (OR, 1.11; 95% CI, 1.10-1.12) relatives. The risk for HT was an additional 2.2- to 2.6-fold higher in female relatives of patients with HT than overall estimates, across all degrees of relatedness. Among first-degree relatives, sons of men with HT had a markedly elevated risk for HT (OR, 2.36; 95% CI, 2.10-2.65). Wives of men with HT and husbands of women with HT were at an increased likelihood of developing HT, suggesting the effect of a shared environment. IN PRACTICE: 'These findings also have clinical implications, as understanding familial clustering of HT can help healthcare providers identify individuals at higher risk, especially those with affected FDRs [first-degree relatives]. This knowledge could lead to earlier monitoring and intervention, improving disease management,' the authors of the study wrote. SOURCE: This study was led by Melissa Bujnis, PhD, Department of Human Genetics, University of Utah, Salt Lake City. It was published online in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: Reliance on diagnostic codes may have introduced misclassification bias, particularly in cases of transient hypothyroidism or misdiagnosed HT. Variations in diagnostic practices across clinics may have introduced heterogeneity in the sample. Individuals with a family history of HT might be more likely to receive diagnosis or seek medical attention, potentially introducing ascertainment bias. DISCLOSURES: Partial support for the datasets in the database was provided by the University of Utah, Huntsman Cancer Institute, National Institutes of Health (NIH). This study received support from NIH, NCRR, and Utah Department of Health and Human Services and the University of Utah. The authors reported no relevant conflicts of interest.
